After a rough regulatory start to the year, India’s Aurobindo Pharma is charting plans for growth. The Hyderabad-based generics juggernaut will plow 3 billion Indian rupees (about $37.7 million) into ...
• The businesses to be acquired provide a broad Western-European pharmaceuticals platform including personnel, commercial infrastructure, products, marketing authorizations and dossier licenses • ...
Aurobindo Pharma shares swung sharply on Wednesday after the company clarified in a filing that talk of a potential $5–5.5 billion buyout of Prague-based Zentiva is “premature” and no binding ...
Aurobindo Pharma has reportedly emerged as the frontrunner to acquire Prague-based generic drugmaker Zentiva for $5–5.5 billion from private equity firm Advent International. The stock was the top ...
Consolidated Revenue: INR8,640 crores, up 8.4% year-on-year. EBITDA: INR1,773 crores with a margin of 20.5%, a 9% year-on-year growth. Formulation Business Revenue: INR7,683 crores, 10% year-on-year ...
Aurobindo Pharma USA Inc., a wholly-owned subsidiary of Aurobindo Pharma, has entered into a definitive agreement to acquire Lannett Company LLC from Lannett Seller Holdco, Inc at an enterprise value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results